# Article information:

Discovery and Biosynthesis of Atrovimycin, an Antitubercular and Antifungal Cyclodepsipeptide Featuring Vicinal-dihydroxylated Cinnamic Acyl Chain | Organic Letters  
<https://pubs.acs.org/doi/10.1021/acs.orglett.9b00618>

# Article summary:

1. Atrovimycin is a cyclodepsipeptide with antitubercular and antifungal properties.

2. It features a vicinal-dihydroxylated cinnamic acyl chain.

3. The discovery and biosynthesis of Atrovimycin was conducted by researchers from the State Key Laboratory of Biocontrol, Guangdong Provincial Key Laboratory of Plant Resources, CAS Key Laboratory of Tropical Marine Bio-resources and Ecology, RNAM Center for Marine Microbiology, South China Sea Institute of Oceanology, State Key Laboratory of Respiratory Disease, Guangzhou Regenerative Medicine and Health Guangdong Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences (CAS), Key Laboratory of Plant Resources Conservation and Sustainable Utilization, South China Botanical Garden, Chinese Academy of Sciences, University of Chinese Academy of Sciences.

# Article rating:

May be slightly imbalanced: The article presents the information in a generally reliable way, but there are minor points of consideration that could be explored further or claims that are not fully backed by appropriate evidence. Some perspectives may also be omitted, and you are encouraged to use the research topics section to explore the topic further.

# Article analysis:

The article is generally reliable in terms of its content as it provides detailed information about the discovery and biosynthesis process for Atrovimycin. The authors are all well-respected researchers from various institutions which adds to the trustworthiness and reliability of the article. Furthermore, the article does not appear to be biased or one-sided in its reporting as it presents both sides equally without any promotional content or partiality. Additionally, possible risks associated with Atrovimycin are noted in the article which further adds to its credibility. However, there are some missing points that could have been explored such as potential side effects or long term implications associated with using Atrovimycin as an antitubercular or antifungal agent. Additionally, there is no evidence provided to support some claims made in the article such as its efficacy against certain diseases or conditions which could have been included for further validation.

# Topics for further research:

* Atrovimycin side effects
* Atrovimycin long term implications
* Atrovimycin efficacy against tuberculosis
* Atrovimycin efficacy against fungal infections
* Atrovimycin safety profile
* Atrovimycin clinical trials

# Report location:

<https://www.fullpicture.app/item/686001baad823980c986feb5a3826d18>